Two of the most discussed investigational compounds in metabolic research are retatrutide and tirzepatide. While both belong to the incretin-based research compound family, they differ fundamentally in receptor targeting, mechanism of action, and the stage of available research data.
This guide provides a research-literacy comparison for Australian researchers evaluating the preclinical and clinical literature on these two compounds.
Receptor Targeting: Dual vs Triple Agonism
The most significant difference between tirzepatide and retatrutide lies in their receptor pharmacology.
Tirzepatide — Dual GIP/GLP-1 Agonist
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It activates both receptors simultaneously, which research suggests may produce additive or synergistic effects on glucose homeostasis and body mass regulation compared to single-target GLP-1 agonism.
Explore tirzepatide research: /peptides/tirzepatide/
Retatrutide — Triple GIP/GLP-1/Glucagon Agonist
Retatrutide goes a step further. It is a triple agonist targeting GIP, GLP-1, and glucagon receptors. The addition of glucagon receptor agonism is a novel research approach — glucagon historically increases hepatic glucose output, but in the context of multi-receptor agonism, it may contribute to increased energy expenditure and lipid oxidation in research settings.
Explore retatrutide research: /peptides/retatrutide/
Key Research Data Comparison
Tirzepatide Research Data
Tirzepatide has progressed further in the research pipeline. Published phase 3 clinical trial data (SURMOUNT programme) has been available in peer-reviewed literature, making it one of the most data-rich incretin compounds in metabolic research. Key findings in published research include:
- Significant reductions in body mass observed across multiple dose cohorts
- Robust effects on glycaemic markers (HbA1c reduction) in type 2 diabetes research models
- Dose-dependent responses across 5mg, 10mg, and 15mg research doses
- Favourable comparison against semaglutide in head-to-head research (SURPASS-2)
Tirzepatide is currently marketed as Mounjaro and Zepbound in certain jurisdictions under specific prescription frameworks.
Retatrutide Research Data
Retatrutide is earlier in the research pipeline. Phase 2 clinical trial data (published in The New England Journal of Medicine, 2023) showed notable research findings:
- Body mass reductions of up to ~24% at the highest dose over 48 weeks in the research cohort
- Dose-dependent and sustained reductions in markers of metabolic health
- Effects on hepatic fat content, suggesting potential research relevance to fatty liver research models
- Multi-receptor engagement producing what researchers describe as a “triple-threat” metabolic profile
Phase 3 research is ongoing at the time of writing, and full regulatory approval status remains pending in most jurisdictions.
Mechanism Differences in Research Context
| Feature | Tirzepatide | Retatrutide |
|---|---|---|
| Receptor targets | GIP + GLP-1 | GIP + GLP-1 + Glucagon |
| Agonist type | Dual | Triple |
| Research phase | Phase 3 complete, marketed | Phase 3 ongoing |
| Key mechanism | Incretin-mediated glucose control + satiety signalling | Incretin effects + glucagon-driven energy expenditure |
| Published trial data | Extensive (SURMOUNT, SURPASS) | Growing (Phase 2 published) |
Australian Research Context
TGA Status
As of the current research landscape, tirzepatide holds TGA registration in Australia under the brand name Mounjaro for specific research-approved indications. It is classified as a Schedule 4 (S4) Prescription Only compound.
Retatrutide does not currently hold TGA registration. In Australia, it remains an investigational research compound — available to researchers under specific import and research-use frameworks but not approved for prescription through standard medical channels.
Access for Researchers
Australian researchers interested in studying these compounds should be aware that:
- Both compounds are classified as research peptides and are subject to TGA import regulations
- Personal importation rules may apply under specific conditions (see: Are Peptides Legal in Australia?)
- Quality and purity verification through third-party testing is a key consideration for research integrity
For discussions on sourcing, testing, and research methodology, join the Grey Highway Telegram community.
Comparing Research Trajectories
Tirzepatide’s research advantage is its maturity — with multiple large-scale phase 3 trials published and commercial availability in several markets. Researchers have access to extensive peer-reviewed data on dosing, pharmacokinetics, and observed outcomes.
Retatrutide’s research appeal lies in its novelty and the addition of glucagon receptor agonism. The phase 2 data showing substantial body mass reductions and effects on hepatic fat markers has generated significant research interest. However, the published evidence base is smaller, and phase 3 outcomes will be critical for understanding the full research profile of this triple agonist.
For researchers choosing between studying these compounds, the decision often comes down to:
- Data availability: Tirzepatide offers a more complete research literature
- Novelty: Retatrutide represents a newer mechanism with potentially different research applications
- Regulatory access: Tirzepatide has established TGA pathways in Australia; retatrutide does not
Frequently Asked Questions
Is retatrutide approved in Australia?
No. Retatrutide does not currently hold TGA registration in Australia. It remains an investigational research compound. Phase 3 clinical research is ongoing globally.
How does retatrutide’s triple agonism differ from tirzepatide’s dual agonism in research?
The primary difference is retatrutide’s additional glucagon receptor agonism. In research contexts, glucagon receptor activation may contribute to increased energy expenditure, hepatic lipid metabolism, and thermogenic effects — mechanisms not engaged by tirzepatide’s GIP/GLP-1 dual agonism alone.
Which compound has more published research data?
Tirzepatide has significantly more published research data, including multiple completed phase 3 trials. Retatrutide has published phase 2 data and ongoing phase 3 studies.
Can Australian researchers legally study retatrutide?
Retatrutide is not TGA-registered, which means it cannot be prescribed through standard Australian medical channels. However, research use and importation may be possible under specific regulatory frameworks. See our guide on peptide legality in Australia for details.
Where can I discuss retatrutide vs tirzepatide research with other Australians?
Join the Grey Highway Telegram community — Australia’s active community of peptide and GLP-1 researchers sharing knowledge, research findings, and regulatory insights.
This guide is for educational and research literacy purposes only. It does not constitute medical or therapeutic advice. All compounds discussed are research compounds, and all information is presented in the context of scientific research interest. Grey Highway supports informed, responsible research literacy for Australian researchers.
Have questions or want to connect with fellow researchers? Join our Telegram community.